Terms: = Lung cancer AND EML4, ENSG00000143924, 27436
837 results:
1. Superparamagnetic Iron Oxide Nanoparticles Reprogram the Tumor Microenvironment and Reduce lung cancer Regrowth after Crizotinib Treatment.
Horvat NK; Chocarro S; Marques O; Bauer TA; Qiu R; Diaz-Jimenez A; Helm B; Chen Y; Sawall S; Sparla R; Su L; Klingmüller U; Barz M; Hentze MW; Sotillo R; Muckenthaler MU
ACS Nano; 2024 Apr; 18(17):11025-11041. PubMed ID: 38626916
[TBL] [Abstract] [Full Text] [Related]
2. [A case of crizotinib-associated renal cysts].
Quan LL; Huang P; Liang YC; Chen FW; Liu SB; Xin WW
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):356-359. PubMed ID: 38599812
[TBL] [Abstract] [Full Text] [Related]
3. Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
Nakazawa M; Harada G; Ghanem P; Bubie A; Kiedrowski LA; Murray JC; Marrone KA; Scott SC; Houseknecht S; Falcon CJ; Evans P; Feliciano J; Hann CL; Ettinger DS; Smith KN; Anagnostou V; Forde PM; Brahmer JR; Levy B; Drilon A; Lam VK
Cancer Res Commun; 2024 Mar; 4(3):786-795. PubMed ID: 38407352
[TBL] [Abstract] [Full Text] [Related]
4. Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.
Yang C; Zeng R; Zha Y; Li Y; Wang T; Zhao R; Li M; Zhang J
Front Immunol; 2024; 15():1360671. PubMed ID: 38380327
[TBL] [Abstract] [Full Text] [Related]
5. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
[TBL] [Abstract] [Full Text] [Related]
6. A novel eml4-NTRK3 fusion in lung adenocarcinoma with dramatic response to entrectinib.
Batra U; Nathany S; Sharma M; Jain P; Mehta A; Bansal A
J Cancer Res Ther; 2023 Oct; 19(7):2045-2047. PubMed ID: 38376315
[TBL] [Abstract] [Full Text] [Related]
7. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.
Rosell R; Pedraz-Valdunciel C; Jain A; Shivamallu C; Aguilar A
Expert Opin Investig Drugs; 2024 Mar; 33(3):171-182. PubMed ID: 38372666
[TBL] [Abstract] [Full Text] [Related]
8. Longitudinal plasma proteomic profiling of eml4-ALK positive lung cancer receiving ALK-TKIs therapy.
Wang S; Hao X; Dai L; Lou N; Fan G; Gao R; Yang M; Xing P; Liu Y; Wang L; Zhang Z; Yao J; Tang L; Shi Y; Han X
Lung Cancer; 2024 Mar; 189():107503. PubMed ID: 38359741
[TBL] [Abstract] [Full Text] [Related]
9. Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer.
Faya Castillo JE; Zapata Dongo RJ; Wong Chero PA; Infante Varillas SF
PLoS One; 2024; 19(2):e0295966. PubMed ID: 38319906
[TBL] [Abstract] [Full Text] [Related]
10. lung carcinoma with diffuse cysts repeatedly misdiagnosed as pulmonary infections and lymphoid interstitial pneumonia: A case report.
Li Y; Lu J; Yuan J
Medicine (Baltimore); 2024 Feb; 103(5):e37002. PubMed ID: 38306516
[TBL] [Abstract] [Full Text] [Related]
11. eml4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation.
Qin Z; Yue M; Tang S; Wu F; Sun H; Li Y; Zhang Y; Izumi H; Huang H; Wang W; Xue Y; Tong X; Mori S; Taki T; Goto K; Jin Y; Li F; Li FM; Gao Y; Fang Z; Fang Y; Hu L; Yan X; Xu G; Chen H; Kobayashi SS; Ventura A; Wong KK; Zhu X; Chen L; Ren S; Chen LN; Ji H
J Exp Med; 2024 Mar; 221(3):. PubMed ID: 38284990
[TBL] [Abstract] [Full Text] [Related]
12. lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-eml4 in combined treatment of Alectinib and CyberKnife: A case report.
Li Y; Lu S; Yao P; Huang W; Huang Y; Zhou Y; Yuan Y; Cheng S; Wu F
Medicine (Baltimore); 2024 Jan; 103(3):e36992. PubMed ID: 38241569
[TBL] [Abstract] [Full Text] [Related]
13. Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report.
Wang Z; Shi Y; Zhang P; Chen Y
Chin Clin Oncol; 2023 Dec; 12(6):70. PubMed ID: 38195077
[TBL] [Abstract] [Full Text] [Related]
14. Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung.
Alidousty C; Becker A; Binot E; Hillmer AM; Merkelbach-Bruse S; Budde B; Bäßmann I; Rappl G; Wolf J; Eich ML; Noh KW; Buettner R; Schultheis AM
Gene; 2024 Feb; 895():148018. PubMed ID: 37981082
[TBL] [Abstract] [Full Text] [Related]
15. eml4-ALK fusion protein in lung cancer cells enhances venous thrombogenicity through the pERK1/2-AP-1-tissue factor axis.
Su Y; Yi J; Zhang Y; Leng D; Huang X; Shi X; Zhang Y
J Thromb Thrombolysis; 2024 Jan; 57(1):67-81. PubMed ID: 37940761
[TBL] [Abstract] [Full Text] [Related]
16. Comparison of gene mutation profile in different lung adenocarcinoma subtypes by targeted next-generation sequencing.
Zhang S; Dong P; Pan Z; Chen Q; Zhu J; Mao Z
Med Oncol; 2023 Nov; 40(12):349. PubMed ID: 37935925
[TBL] [Abstract] [Full Text] [Related]
17. Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive lung cancer: A Case Report.
Li J; Liu J; Zhang G; Hu W; Wang X; Liu J
Am J Case Rep; 2023 Nov; 24():e942150. PubMed ID: 37934724
[TBL] [Abstract] [Full Text] [Related]
18. Transformation of NSCLC to SCLC harboring eml4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract] [Full Text] [Related]
19. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
Sun W; Zheng J; Zhou J; Zhou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):583-587. PubMed ID: 37899398
[TBL] [Abstract] [Full Text] [Related]
20. Non-Small Cell lung cancer: Targetable Variants in Concurrent Tissue and Liquid Biopsy Testing in a North Indian Cohort.
Paturu R; Lingaiah R; Kumari N; Singh S; Krishnani N; Srivastava S; Siddiqui SH; Nath A
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3467-3475. PubMed ID: 37898852
[TBL] [Abstract] [Full Text] [Related]
[Next]
